Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
Sales | 6,960,000 | 7,301,801 | 6,941,600 | 6,488,000 | 7,810,000 |
Cost of Goods | 1,626,700 | 1,548,100 | 1,579,100 | 1,430,500 | 2,072,100 |
Gross Profit | 5,333,300 | 5,753,700 | 5,362,500 | 5,057,500 | 5,737,900 |
Operating Expenses | 3,840,000 | 3,917,399 | 3,686,100 | 3,847,900 | 3,333,700 |
Operating Income | 1,494,000 | 1,836,400 | 1,676,500 | 1,210,100 | 2,404,300 |
Other Income | 35,700 | 260,000 | -111,000 | -119,200 | -350,700 |
Pre-tax Income | 1,529,700 | 2,096,400 | 1,565,500 | 1,090,900 | 2,053,600 |
Income Tax | 184,800 | 158,700 | 113,800 | 138,400 | 150,700 |
Net Income Continuous | 1,344,900 | 1,937,699 | 1,451,700 | 952,500 | 1,902,900 |
Net Income | $1,344,900 | $1,937,699 | $1,451,700 | $952,500 | $1,902,900 |
EPS Basic Total Ops | 1.49 | 2.15 | 1.61 | 1.06 | 2.11 |
EPS Basic Continuous Ops | 1.49 | 2.15 | 1.61 | 1.06 | 2.11 |
EPS Diluted Total Ops | 1.49 | 2.14 | 1.61 | 1.05 | 2.10 |
EPS Diluted Continuous Ops | 1.49 | 2.14 | 1.61 | 1.05 | 2.10 |
EPS Diluted Before Non-Recurring Items | 1.62 | 2.09 | 1.98 | N/A | N/A |
EBITDA(a) | $1,856,300 | $2,211,401 | $2,039,401 | $1,559,000 | $2,840,000 |